-- Transformational degrader antibody conjugate company backed by leading syndicate including founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly & Company --
Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng...
Clarius Invents a New Way to Help Clinicians Instantly Identify Ultrasound Anatomy
AIT365 News Desk -
T-Mode TM AI by Clarius creates a split screen during an exam that displays a colorful anatomical image with labels next to the grayscale ultrasound image
Clarius Mobile Health, a global leader in wireless ultrasound solutions, announces T-ModeTM AI, a groundbreaking educational technology to help clinicians who are new to ultrasound advance their image...
VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
AIT365 News Desk -
Collaboration to leverage VantAI's expertise in generative AI and geometric deep learning to identify molecular glues against targets of interest with an option to expand to additional programs
VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb, a leading pharmaceutical company, have entered into a strategic...
Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics
AIT365 News Desk -
Roche announced that it has entered into an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology.
Under the terms of this agreement, PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in the companion diagnostics space. RTD will work...
Enable Medicine, a leader in AI for biological research and drug discovery, has announced the appointment of Kamni Vijay as Chief Executive Officer. She succeeds co-founder Sunil Bodapati, who developed Enable Medicine’s strategy and closed Series A financing in 2022. Mr. Bodapati remains Chairman of the Board and will...
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
AIT365 News Desk -
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability
BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the U.S. Food...
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions
AIT365 News Desk -
Centralized data science platform streamlines clinical study data management for swift, insight-driven clinical decisions and therapeutic advancements
Revvity, Inc. announced that its software and informatics division, Revvity Signals, is unveiling the Signals Clinical solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable...
Saama and Pfizer Expand Agreement to Integrate AI-Driven Data Solutions Across R&D Portfolio
AIT365 News Desk -
Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, announced a newly expanded, multi-year agreement with global biopharmaceutical leader Pfizer to help expedite clinical research.
The agreement represents the expansion of a strategic relationship that began in 2020 when Saama and Pfizer entered into a partnership to automate...
Meliora Therapeutics Establishes Leadership Team with Key Promotion and New Addition
AIT365 News Desk -
Meliora Therapeutics, a machine learning therapeutics company developing novel and transformative cancer drugs, announced the promotion of Claudio Chuaqui, Ph.D., to Chief Scientific Officer (CSO), and the appointment of Anand Selvaraj, Ph.D. as Vice President and Head of Cancer Biology.
“These leadership updates mark the beginning of a new phase...
Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures
AIT365 News Desk -
Advances in AI Platform Provide an Ability to Rapidly Predict, Identify and Design Biomolecular Structures to Accelerate the Pace and Reduce the Cost of Drug Discovery and Development
Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, announced the publication of research in Nature...